Home > Plavix >

Plavix In The News

Analyst expects aggressive M&A in big pharma

Large mergers and buyouts may be on the way in the pharmaceutical sector, a Deutsche Bank analyst said, because drug makers can't keep up their current level of spending in the face of expiring patents and conservative regulators.

(AFX UK Focus) 2008-11-27 08:57 UPDATE 2-Sanofi's Multaq to get U.S. panel review in March

PARIS, Nov 27 (Reuters) - Sanofi-Aventis' experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, marking a delay in a priority review by the health regulator. The world's No.3 drugmaker said on Thursday the advisory panel on Multaq, which some analysts forecast could yield more than $2 billion in annual sales, would meet on March 18. ...

Sanofi Raised to `Overweight' at Morgan Stanley on Cost Cuts

Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France's largest drugmaker, was raised to ``overweight' from ``equal weight' at Morgan Stanley, which said its new chief executive, Chris Viehbacher , was likely to cut research expenses.

Schering-Plough touts pipeline over competitors'

Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday. The drugmaker has three drugs awaiting U.S. approval and nine more in final human testing - including a new type of anticlotting drug that could grab some of blockbuster ..

Sanofi-Aventis Upped To Overweight By Morgan Stanley

Sanofi-Aventis Upped To Overweight By Morgan Stanley

Sanofi Gains Most Since 1989 on Morgan Stanley Rating (Update1)

Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in 19 years in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”

Sinking feeling in the eurozone

The news from continental Europe has been unremittingly grim in recent weeks.

Schering's Peacock Imitation

The company lays out its pipeline for investors to digest.

Sanofi Gains After Morgan Stanley Raises Rating, Price Estimate

Nov. 24 (Bloomberg) -- Sanofi-Aventis SA , France’s largest drugmaker, increased the most in five weeks in Paris trading after Morgan Stanley analysts raised the rating on the stock to “overweight” from “equal weight.”

Schering-Plough touts pipeline over competitors'

Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.

* First Name:

* Last Name:

* Email:

* Phone:

Our 'Smart Form' automatically routes your case evaluation to the correct county/city based on your zip code.

* Zip Code:
Comments

When authoring your comments please try to include the Who? What? Where? When? and How?

The more information our attorneys have the better they can evaluate your potential claim.